IPC inks agreement with U-Save pharmacy group
SUN PRAIRIE, Wis. — The Independent Pharmacy Cooperative announced Friday that it had signed an agreement with Nebraska-based U-Save pharmacy group. The new partnership will bring access to IPC’s resources to U-Saves more than 80 U-Save independent pharmacies across North Dakota, South Dakota, Nebraska, Iowa, Kansas, Missouri, Colorado, Wisconsin, and Minnesota.
“We are proud to have the U-Save stores as the newest group to partner with IPC to further strengthen our position in the marketplace to attain even better opportunities for our member stores and to improve the climate for independent pharmacy in the marketplace,” IPC President and CEO Don Anderson said. “IPC is poised to push for greater results on the political stage as well as continuing our efforts to deliver the solutions today’s independent pharmacy needs to thrive.”
The new IPC members will have access to more than 70 contracted vendors delivering negotiated pricing and additional value, as well as the opportunities that come from IPC’s supply agreement with McKesson.
“Our stores are excited to take this step with IPC,” the U-Save buying group team said. “This is a perfect alignment of community pharmacy groups with a common goal. We look forward to being part of the IPC effort to influence positive outcomes for community pharmacy. I know our members will benefit greatly from this alliance and will be active participants in the many programs provided by IPC for independent pharmacy success.”
Good Neighbor Pharmacy launches DIR fee estimator tool
VALLEY FORGE, Pa. — Good Neighbor Pharmacy on Friday announced a new tool for independent pharmacists designed to help them plan around direct and indirect remuneration, or DIR, fees and hidden cash flow issues surrounding them.
“For more than 30 years, we have found our greatest successes when we listen to our pharmacists and develop solutions that address the most complicated challenges they face every day,” AmerisourceBergen group VP pharmacy innovation and solutions Chuck Reed said. “Inconsistency and opacity in how DIR fees are calculated and the delayed timing of DIR fees is a major pain point for pharmacists.”
The new tool is available to members of AmerisourceBergen’s pharmacy services administrative organization, Elevate Provider Network, who take advantage of its advanced features. The DIR fee estimator tool uses real-time claim-level detail alongside DIR rates from signed contracts between the PSAO and pharmacy benefits managers. The tool is updated every two hours to ensure the most accurate information is available for pharmacists planning around their monthly fees.
“Our DIR fee estimator tool was created to empower them to plan ahead, give [pharmacists] visibility into the process and ultimately set them up for a more successful business,” Reed said.
The company said that the estimator tool is part of its larger efforts to manage the impact that DIR fees have on independent pharmacies, including work through Elevate Provider Network’s approach to managed care contracting and selectively participating in preferred cost-sharing networks. The company also advocates on behalf of independent and managed-care pharmacies on legislative issues, and has a resource site for pharmacists, OurIndependentVoice.com.
FDA approves Janssen’s plaque psoriasis drug Tremfya
SILVER SPRING, Md. — The Food and Drug Adminisration has approved Janssen Biotech’s new treatment for plaque psoriasis, the company announced Thursday. Tremfya (guselkumab) is the first drug to be approved that selectively blocks a key plaque psoriasis cytokine, the company said.
“Addressing the need for additional safe and effective plaque psoriasis therapies has been a critical area of focus at Janssen for more than 15 years,” Janseen VP medical affairs Dr. Andrew Greenspan said. “Considering this, we applied a priority review voucher to the application for Tremfya to bring this novel treatment to patients sooner.”
The drug is indicated for moderate to severe plaque psoriasis patients who are candidates for systemic therapy or phototherapy.
"Living with plaque psoriasis is challenging, especially the constant pain, itching and burning," said Patti Janick, a guselkumab clinical trial participant. "I am encouraged by the results I've experienced with TREMFYA™ and the possibility it offers others living with plaque psoriasis to find similar relief and clearer skin."
Janssen said it would work with payers, providers and pharmacy benefits managers to ensure broad accessibility and affordability for patients, and that the cost for payers is competitive with currently available psoriasis biologic treatments.